Research Studies

This (fully enrolled) ongoing ten year in-person program is part of an industry-sponsored international effort to follow the clinical course and natural history of XLH in a detailed, systematic manner. The study incorporates children and adults undergoing various (or no) therapies, and collects, clinical, laboratory and imaging data.

This industry-sponsored ongoing program will follow the clinical course and natural history of TIO in a similar manner.

In response to application of burosumab in patients with XLH.

• Osteogenesis lmperfecta: Use of sertrusumab, an anti-sclerostin antibody, in the treatment of osteogenesis imperfecta
• Use of fresolimumab, an anti-TGFb antibody, in the treatment of adults with 01.

This industry-sponsored ongoing program will follow the clinical course and natural history of individuals affected with hypoparathyroidism and autosomal dominant hypocalcemia over time.